

ASSISTANT COMMISSIONER FOR PATENTS  
Washington, DC 20231



Docket No.: 200.1079CON4  
Date: November 22, 2002

In re application of: Ronald M. BURCH, et al.  
Serial No.: 10/056,348  
Filed: January 25, 2002  
For: ANALGESIC COMBINATION OF OXYCODONE AND NAMUMETONE

Sir:

Transmitted herewith is a **Preliminary Amendment** in the above-identified application.


- Small entity status under 37 C.F.R. 1.9 and 1.27 has been previously established.
- Applicants assert small entity status under 37 C.F.R. 1.9 and 1.27.
- No fee for additional claims is required.
- A filing fee for additional claims calculated as shown below, is required:

FOR:	(Col. 1)		(Col. 2)		SMALL ENTITY RATE	OR	LARGE ENTITY RATE
	REMAINING	HIGHEST	AFTER	PREVIOUSLY			
		AMENDMENT	PAID FOR	EXTRA			
TOTAL CLAIMS	* Minus** =				x \$ 9   \$		x \$ 18   \$
INDEP. CLAIMS	* Minus*** =				x \$ 42   \$		x \$ 84   \$
[ ] FIRST PRESENTATION OF MULTIPLE DEP. CLAIM					+ \$140   \$		+ \$280   \$

TOTAL: \$                  OR TOTAL: \$                 


- \* If the entry in Co. 1 is less than the entry in Col. 2, write "0" in Col. 3.
- \*\* If the "Highest Number Previously Paid For" IN THIS SPACE is less than 20, write "20" in this space.
- \*\*\* If the "Highest Number Previously Paid For" IN THIS SPACE is less than 3, write "3" in this space.

- Also transmitted herewith are:
  - Petition for extension under 37 C.F.R. 1.136 (in duplicate)
  - Other: **Information Disclosure Statement (3 pages)**  
 Form PTO-1449 (3 pages)  
 Exhibit A (15 pages)
- Check(s) in the amount of \$0.00 is/are attached to cover:
  - Filing fee for additional claims under 37 C.F.R. 1.16
  - Petition fee for extension under 37 C.F.R. 1.136
  - Other:
- The Assistant Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 50-0552.
  - Any filing fee under 37 C.F.R. 1.16 for the presentation of additional claims which are not paid by check submitted herewith.
  - Any patent application processing fees under 37 C.F.R. 1.17.
  - Any petition fees for extension under 37 C.F.R. 1.136 which are not paid by check submitted herewith, and it is hereby requested that this be a petition for an automatic extension of time under 37 CFR 1.136.

  
 Robert J. Paradiso, Reg. No. 41,240  
 DAVIDSON, DAVIDSON & KAPPEL, LLC  
 485 Seventh Avenue, 14<sup>th</sup> Floor  
 New York, New York 10018  
 Tel: (212) 736-1940  
 Fax: (212) 736-2427

I hereby certify that this correspondence and/or documents referred to as attached therein and/or fee are being deposited with the United States Postal Service as "first class mail" in an envelope addressed to "Assistant Commissioner for Patents, Washington, D.C. 20231" on November 22, 2002.

DAVIDSON, DAVIDSON & KAPPEL, LLC

BY: 



200.1079.CON4

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Re: Application of: Ronald M. BURCH, et al.

**RECEIVED**

Serial No. 10/056,348

DEC 04 2002

Filed: January 25, 2002

TECH CENTER 1600/2900

For: **ANALGESIC COMBINATION OF OXYCODONE  
AND NABUMETONE**

**PRELIMINARY AMENDMENT**

BOX Non-Fee Amendment  
Assistant Commissioner for Patents  
Washington, D.C. 20231

November 22, 2002

Sir:

Applicants respectfully request that the following amendments be made to the above-mentioned application:

**IN THE SPECIFICATION**

Please amend the **specification** as follows:

At page 13, please amend the paragraph beginning at line 25 as follows:

B1  
- - Certain preferred COX-2 inhibitors include celecoxib (SC-58635), 5-bromo-s-(4-fluorophenyl)-3-[4-(methylsulfonyl)phenyl] thiophene (DUP-697), flosulide (CGP-28238), meloxicam, 6-methoxy-2 naphthylacetic acid (6-MNA), Vioxx (MK-966), nabumetone (prodrug for 6-MNA), nimesulide, N-[2-(cyclohexyloxy)-4-nitrophenyl] methanesulfonamide (NS-398), 1-fluoro-4-[2-[4-methylsulfonyl)phenyl]-1-cyclopenten-1-yl] benzene (SC-5766), 5-(4-fluorophenyl)-1[4-(methylsulfonyl)phenyl]-3-trifluoromethyl 1H-pyrazole (SC-58215), N-[3-